MOLOGEN Lifescience AG Stock: price and insider trades · Germany

No insider purchase over the last 90 days. The latest was filed 10 Apr 2026.

MOLOGEN Lifescience AG: what insiders have been doing

MOLOGEN Lifescience AG has a thin disclosure history in our data (latest filing: 10 April 2026). New filings will appear here as soon as they are published. These figures are compiled from regulatory filings published by BaFin. They describe what insiders did and are not a recommendation.

Insider Decl.

Thresholds

n/a

Buy Volume

€150,000

1 ops. · all time

Sell Volume

n/a

Who traded when

BuySale

Matthias Bäumler2 buys

Financial data

· cache

Last declaration on 10 April 2026

Declarations1 total

▲

Matthias Bäumler

Supervisory boardExecutives7 Apr 2026

€150k15BaFin ↗

50,000 shares@ €3.00100.0% of flowShareDE000A3MQC96BAFIN:40024888

Canonical exit: 6 Jul 2026 (T+90)

1 of 1 declaration

About MOLOGEN Lifescience AG

MOLOGEN Lifescience AG is a German listed company traded on Xetra/Frankfurt (DAX/MDAX/SDAX) and headquartered in Hamburg, Germany. The company’s background is unusual: it originates from the former Mologen AG, which was historically known as a biotechnology business, but the group has since undergone a substantial restructuring and rebranding. In its current form, MOLOGEN Lifescience AG reflects a life-sciences oriented profile with a broader and more adaptable mandate than a classic clinical-stage biotech company. Recent public disclosures show the transition from Finchain Capital Partners AG to MOLOGEN Lifescience AG, alongside corporate actions and capital measures that indicate a strategic reset. ([live.deutsche-boerse.com](https://live.deutsche-boerse.com/nachrichten/Finchain-Capital-Partners-AG-FINICHAIN-Capital-Partners-AG-plant-Beschlussfassung-ueber-Umfirmierung-und-Barkapitalerhoehung-mit-Bezugsrechtsausschluss-16d3a194-43b0-4cfb-a553-47e9982850cd?utm_source=openai))

From an analyst’s perspective, the company sits within the healthcare / biotech universe, but its operational profile appears closer to a life-science investment and development platform than to a fully integrated pharmaceutical business. Publicly available information suggests exposure to several health-related themes, including life-science development, digital health, medical services, and related participations or investments. That structure implies a capital-allocation-driven model rather than a large-scale industrial operating business. As a result, execution risk, funding capacity, and the ability to create value through selected assets are likely more important than traditional revenue mix analysis at this stage. ([companyhouse.de](https://www.companyhouse.de/Gabriel-Salgo?utm_source=openai))

Read moreShow less

A key part of the company’s history is the break from its former biotechnology trajectory. The legacy Mologen business went through severe distress, including insolvency proceedings several years ago, which is highly relevant for investors assessing the current equity story. More recently, official market disclosures point to a successful recapitalization and a new corporate identity, suggesting an attempt to rebuild the shareholder base and financial foundation. For French-speaking investors, this is best viewed as a German small-cap turnaround story in the life sciences space, with a much more speculative risk profile than an established commercial healthcare company. ([live.deutsche-boerse.com](https://live.deutsche-boerse.com/nachrichten/MOLOGEN-Lifescience-AG-Finchain-Capital-Partners-AG-firmiert-kuenftig-als-MOLOGEN-Lifescience-AG---Kapitalerhoehung-erfolgreich-abgeschlossen-9fd39386-2e77-4539-b49c-1a2d184fa48c?utm_source=openai))

In terms of competitive position, MOLOGEN Lifescience AG does not currently appear to have the commercial scale, product visibility, or recurring revenue base of a mid-sized pharma or diagnostics group. Its market relevance lies more in the transformation story, balance-sheet events, governance changes, and potential future investment announcements. Recent regulatory communications also include directors’ dealings notifications under MAR Article 19, underscoring active BaFin-level market surveillance and continued insider-reporting discipline. ([de.tradingview.com](https://de.tradingview.com/news/reuters.com%2C2026-04-10%3Anewsml_Pexc8Krca%3A0/?utm_source=openai))